Abstract 11946: Effect of Evolocumab on Non-high-density Lipoprotein Cholesterol and Apolipoprotein B Levels: An Analysis of Double-blind and Open-label Extension Studies
2019
Introduction: Dyslipidemia guidelines have recommended non-HDL-C and ApoB either as co-primary or secondary targets of therapy. Objective: To evaluate the effect of evolocumab on non-HDL-C and ApoB...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI